Glucose-6-phosphate dehydrogenase deficiency: Difference between revisions
Line 46: | Line 46: | ||
[[Glucose-6-phosphate dehydrogenase deficiency case study one|Case #1]] | [[Glucose-6-phosphate dehydrogenase deficiency case study one|Case #1]] | ||
==Risk Factors== | ==Risk Factors== | ||
* Ethnic groups | * Ethnic groups |
Revision as of 18:08, 21 September 2012
For patient information click here
Template:DiseaseDisorder infobox
Glucose-6-phosphate dehydrogenase deficiency Microchapters |
Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Glucose-6-phosphate dehydrogenase deficiency On the Web |
American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency |
Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency |
Risk calculators and risk factors for Glucose-6-phosphate dehydrogenase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.D. [2]
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | Chest X Ray | CT | MRI | Echocardiography or Ultrasound | Other Imaging Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies
Case Studies
Risk Factors
- Ethnic groups
- African American
- Middle Eastern decent, particularly Kurdish or Sephardic Jewish
- Male
- Family history of the deficiency
Pathophysiology
- Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme in the pentose phosphate pathway, a metabolic pathway that supplies reducing energy to cells (most notably erythrocytes) by maintaining the level of the co-enzyme nicotinamide adenine dinucleotide phosphate (NADPH).
- The NADPH in turn maintains the level of glutathione in these cells that helps protect the red blood cells against oxidative damage. G6PD converts glucose-6-phosphate into 6-phosphoglucono-δ-lactone and is the rate-limiting enzyme of the pentose phosphate pathway.
- Patients with G6PD deficiency are at risk of hemolytic anemia in states of oxidative stress. This can be in severe infection, medication and certain foods. Broad beans contain high levels of vicine, divicine, convicine and isouramil — all are oxidants.
- In states of oxidative stress, all remaining glutathione is consumed. Enzymes and other proteins (including hemoglobin) are subsequently damaged by the oxidants, leading to electrolyte imbalance, membrane cross-bonding and phagocytosis and splenic sequestration of red blood cells. The hemoglobin is metabolized to bilirubin (causing jaundice at high concentrations) or excreted directly by the kidney (causing acute renal failure in severe cases).
- Deficiency of G6PD in the alternative pathway causes the build up of glucose and thus there is an increase of advanced glycation endproducts (AGE). The deficiency also causes a reduction of NADPH which is necessary for the formation of Nitric Oxide (NO). The high prevalence of diabetes mellitus type 2 and hypertension in Afro-Caribbeans in the West could be directly related to G6PD deficiency.[1]
- Some other epidemiological reports have pointed out, however, that G6PD seems to decrease the susceptibility to cancer, cardiovascular disease and stroke.
- Although female carriers can have a mild form of G6PD deficiency (dependent on the degree of inactivation of the unaffected X chromosome - see lyonization), homozygous females have been described; in these females there is co-incidence of a rare immune disorder termed chronic granulomatous disease (CGD).
History and Symptoms
History
- Patients are almost exclusively male, due to the X-linked pattern of inheritance, but female carriers can be clinically affected due to lyonization where random inactivation of an X-chromosome in certain cells creates a population of G6PD deficient red cells coexisting with normal red cells.
- History of hemolytic crises occurs 2-4 days in response to:
- Certain drugs:
- Primaquine (an antimalarial)
- Sulphonamide antibiotics
- Sulphones (e.g. dapsone, used against leprosy)
- Other sulphur-containing drugs: glibenclamide (an anti-diabetic drug)
- Nitrofurantoin (an antibiotic often used for urinary tract infections)
- Vitamin K analogues
- Several others[2]
- Henna can cause a haemolytic crisis in G6PD deficient infants.[3]
- Certain foods, most notably broad beans
- Illness (severe infections)
- Diabetic ketoacidosis
- Certain drugs:
Symptoms
- Symptoms suggestive of anemia such as fatigue, palpitation
- Prolonged jaundice
- Hemolytic features like dark colored urine
- Abdominal or back pain
- Very severe crises can cause acute renal failure
Diagnosis
Laboratory diagnosis
The diagnosis is generally suspected when patients from certain ethnic groups develop anemia, jaundice and symptoms of hemolysis after challenge to any of the above causes, especially when there is a positive family history. The hemolysis spontaneously resolves in approximately 1 week as the older enzyme-depleted cells are replaced by new cells with sufficient G6PD to prevent further hemolysis.
Generally, tests will include:
- Complete blood count - Hemoglobin decreases by 3-4 g/dL
- Increased reticulocyte count
- Haptoglobin (decreased in hemolysis)
- Liver enzymes (to exclude other causes of jaundice)
- TSH measurement.
- A "direct antiglobulin test" (Coombs' test) - this should be negative, as hemolysis in G6PD is not immune-mediated
- Since, reticulocytes can have normal G6PD levels, measuring G6PD levels during an acute episode may produce a false-negative result.
Specific tests for G6PD anemia
- Heinz bodies
- Beutler fluorescent spot test
- The Motulsky dye-decolouration test
- Direct DNA testing and/or sequencing of the G6PD gene.
Heinz bodies: Early diagnosis
When a macrophage in the spleen "sees" an RBC with a Heinz body, it removes the precipitate and a small piece of the membrane, leading to characteristic "bite cells". However, if a large number of Heinz bodies are produced, as in the case of G6PD deficiency, some Heinz bodies will nonetheless be visible when viewing RBCs that have been stained with crystal violet. This easy and inexpensive test can lead to an initial presumption of G6PD deficiency, which can be confirmed with the other tests.
Beutler fluorescent spot test: Late diagosis
The Beutler fluorescent spot test is a rapid and inexpensive test that visually identifies NADPH produced by G6PD under ultraviolet light. When the blood spot does not fluoresce, the test is positive; it can be false-positive in patients who are actively hemolysing. It can therefore only be done several weeks after a hemolytic episode.
Bite or Blister cells
- In glucose-6-phosphate dehydrogenase deficiency, "bite" or "blister" cells are produced when accumulated oxidized hemoglobin remains adherent to the erythrocyte membrane, which creates an adjacent membrane-bound clear zone.
Treatment
- In the acute phase of hemolysis, blood transfusions might be necessary. Blood transfusion is an important symptomatic measure, as the transfused red cells are generally not G6PD deficient.
- Dialysis in acute renal failure
- Some patients benefit from removal of the spleen (splenectomy), as this is an important site of red blood cell destruction. * Folic acid should be used in any disorder featuring a high red blood cell turnover.
- Although vitamin E and selenium have antioxidant properties, their use does not decrease the severity of G6PD deficiency.
Primary Prevention
- The most important measure is prevention - avoidance of the drugs and foods that cause hemolysis.
- Vaccination against some common pathogens (e.g. hepatitis A) may prevent infection-induced attacks.
References
- ↑ Gaskin RS, Estwick D, Peddi R (2001). "G6PD deficiency: its role in the high prevalence of hypertension and diabetes mellitus". Ethnicity & disease. 11 (4): 749–54. PMID 11763298.
- ↑ "The G6PD Deficiency Homepage -- Table 2". Retrieved 2007-10-28.
- ↑ Raupp P, Hassan JA, Varughese M, Kristiansson B (2001). "Henna causes life threatening haemolysis in glucose-6-phosphate dehydrogenase deficiency". Arch. Dis. Child. 85 (5): 411–2. PMID 11668106.
bn:গ্লুকোজ-৬-ফসফেট ডিহাইড্রোজেনেজ স্বল্পতা bg:Глюкозо-6-фосфатдехидрогеназна недостатъчност de:G6PD-Mangel hr:Manjak enzima glukoza-6-fosfat dehidrogenaze he:חוסר G6PD simple:Favism th:โรคพร่องเอนไซม์ G-6-PD